Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8bio, Inc. has put a new at-the-market stock offering program in place and ended its prior one. On June 1, 2026, the company entered into a Capital on Sales Agreement with JonesTrading Institutional Services, allowing IN8bio to issue and sell common stock from time to time at its sole discretion under its existing Form S-3 shelf registration. JonesTrading will use commercially reasonable efforts to sell any shares and will earn a 3.0% commission on gross sales proceeds, while IN8bio has no obligation to sell any stock and either party can terminate the agreement on written notice.
The company also terminated its earlier Controlled Equity Sales Agreement with Cantor Fitzgerald & Co., effective May 29, 2026. Both parties waived the original advance notice requirements, and IN8bio is not subject to any termination penalties. After this termination, no additional shares may be issued or sold under the Cantor agreement or its related prospectus.
IN8bio, Inc. is registering an at-the-market offering to sell up to $2,800,000 aggregate offering price of its common stock through JonesTrading Institutional Services LLC under a Sales Agreement. Sales may occur from time to time at prevailing market prices; JonesTrading will act as agent (or principal) and receive 3.0% of gross proceeds as compensation.
The prospectus supplement ties the offering to our existing Form S-3 shelf and states shares outstanding were 9,847,089 as of March 31, 2026. The filing discloses the aggregate market value of common stock held by non-affiliates as $17,932,668 as of June 1, 2026 (based on 9,589,662 non-affiliate shares at $1.87). Proceeds, if any, are intended for clinical development, working capital and general corporate purposes.
IN8bio, Inc. investors Emily and Malcom Fairbairn amended their Schedule 13D to report a major reduction in ownership. Their charitable remainder unitrust (CRUT) transferred 724,637 shares of common stock to a 501(c)(3) foundation for no consideration on May 27, 2026.
After this transfer, Emily Fairbairn beneficially owns 215,431 shares, or 2.2% of IN8bio’s outstanding common stock, and Malcom Fairbairn beneficially owns 205,626 shares, or 2.1%. The CRUT itself beneficially owns 202,582 shares, also 2.1%, based on 9,847,089 shares outstanding as of May 4, 2026. The reporting persons state they ceased to be beneficial owners of more than five percent on May 27, 2026.
IN8BIO, INC. director Emily Fairbairn reported an indirect transfer of common stock. On May 27, 2026, an entity associated with her made a bona fide gift of 724,637 shares of common stock at $0.00 per share to a 501(c)(3) charitable foundation. After this gift, she continued to report indirect holdings of 923 shares through the Malcom and Emily Fairbairn 2010 CRUT and 3,044 shares through Valley High Limited Partnership, while the Roth IRA account that made the gift reported no remaining shares.
IN8bio, Inc. filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration to update disclosures and file an updated auditor consent. The prospectus covers the offer and sale, from time to time, of up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units.
The shelf permits offerings in one or more combinations and will be supplemented by prospectus supplements that set specific terms, pricing and distribution methods. The company’s common stock trades on the Nasdaq Capital Market under the symbol INAB (last reported sale $1.49 per share on May 15, 2026). The prospectus states net proceeds are intended for working capital and general corporate purposes, and discloses an aggregate market value of common stock held by non-affiliates of $17,631,022 (based on 8,815,511 non-affiliate shares at $2.00 per share on March 20, 2026).
IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.
The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.
IN8BIO director Greenwood Luba received a stock option grant for 22,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. One-twelfth of the shares vest monthly starting June 9, 2026, with full vesting at the next annual stockholders’ meeting if service continues.
IN8BIO, INC. executive Lawrence Lamb, EVP and CSO, received an employee stock option grant covering 54,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. After this grant, Lamb holds options for 54,000 shares directly.
According to the vesting terms, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to Lamb continuing to provide service through each vesting date.
IN8BIO, INC. director Emily Fairbairn received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in 12 equal monthly installments starting on June 9, 2026 and will in any case be fully vested on the date of the company’s next annual meeting of stockholders, subject to her continued service. These options expire on May 9, 2036, and following this grant she holds 22,000 stock options directly.